Actively Recruiting
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Led by Sun Yat-sen University · Updated on 2026-05-11
380
Participants Needed
3
Research Sites
307 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy (CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life in two groups.
CONDITIONS
Official Title
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed with nasopharyngeal non-keratinizing carcinoma (WHO II/III)
- All genders, aged 18 to 70 years
- Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
- Clinical stage T4N1M0 or T1-4N2-3M0 (AJCC/UICC 8th edition)
- No prior radiotherapy, chemotherapy, or other anti-tumor treatments including immunotherapy
- No contraindications to chemotherapy, radiotherapy, or immunotherapy
- Adequate organ function including minimum counts for white blood cells, neutrophils, hemoglobin, and platelets
- Liver enzymes less than 2.5 times upper limit of normal
- Kidney function with blood urea nitrogen or creatinine less than 1.5 times upper limit or creatinine clearance at least 60 ml/min
- Signed informed consent form
You will not qualify if you...
- Presence of distant metastases
- Diagnosis of keratinized squamous cell carcinoma or basal cell-like squamous cell carcinoma
- Current or past other malignant tumors
- Participation in other clinical trials
- Pregnancy or breastfeeding
- Uncontrolled cardiovascular disease
- Severe complications such as uncontrolled hypertension
- Mental disorders
- Drug or alcohol addiction
- Lack full legal capacity for civil acts
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Cancer Center, Sun Yat-sen University
Guangzhou, Guangdong, China
Actively Recruiting
2
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
Not Yet Recruiting
3
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
Not Yet Recruiting
Research Team
C
Chong Zhao, MD, PhD
CONTACT
J
Jingjing Miao, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here